TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Hospitals, doctors in Pa. received $32M in 5 months from drug, medical device companies
  2. Google Pittsburgh instrumental in fight against hackers, co-directors say
  3. LNG exports get federal approval from Dominion’s Cove Point terminal
  4. Retirement planning is about more than just money
  5. EPA says greenhouse gas releases from wells, pipelines decline
  6. Shareholders cheer eBay’s decision to spin off PayPal
  7. Western Pa. unemployment rate holds steady in August
  8. ‘Tug of war’ takes effect on stocks as market logs 3rd monthly drop for 2014
  9. Trib 30 index of Pittsburgh-area stocks falls in September
  10. Education spending helps to widen wealth gap
  11. Study: Wellness programs don't save money, but employee health improves
Subscribe today! Click here for our subscription offers.